| Literature DB >> 28891034 |
Qi Tian1, Pavel Gromov2, Joachim H Clement3, Yingming Wang1, Marc Riemann4, Falk Weih4, Xiao-Xin Sun5, Mu-Shui Dai5, Lev M Fedorov6,7.
Abstract
The mechanistic target of rapamycin (mTOR), a protein kinase, is a central regulator of mammalian metabolism and physiology. Protein mTOR complex 1 (mTORC1) functions as a major sensor for the nutrient, energy, and redox state of a cell and is activated by ras homolog enriched in brain (RHEB1), a GTP-binding protein. Increased activation of mTORC1 pathway has been associated with developmental abnormalities, certain form of epilepsy (tuberous sclerosis), and cancer. Clinically, those mTOR-related disorders are treated with the mTOR inhibitor rapamycin and its rapalogs. Because the effects of chronic interference with mTOR signaling in the aged brain are yet unknown, we used a genetic strategy to interfere with mTORC1 signaling selectively by introducing mutations of Rheb1 into the mouse. We created conventional knockout (Rheb1 +/- ) and gene trap (Rheb1 Δ/+ ) mutant mouse lines. Rheb1-insufficient mice with different combinations of mutant alleles were monitored over a time span of 2 years. The mice did not show any behavioral/neurological changes during the first 18 months of age. However, after aging (> 18 months of age), both the Rheb1 +/- and Rheb1 Δ /- hybrid males developed rare stress-induced seizures, whereas Rheb1 +/- and Rheb1 Δ /- females and Rheb1 Δ/+ and Rheb1 Δ/Δ mice of both genders did not show any abnormality. Our findings suggest that chronic intervention with mTORC1 signaling in the aged brain might be associated with major adverse events.Entities:
Keywords: Gene targeting; Mice; Rapamycin; Rheb1; mTOR inhibitor; mTORC1
Mesh:
Substances:
Year: 2017 PMID: 28891034 PMCID: PMC5745219 DOI: 10.1007/s11357-017-9997-3
Source DB: PubMed Journal: Geroscience ISSN: 2509-2723 Impact factor: 7.713